Langer-backed Sig­ilon sets sail with $23M and new ‘liv­ing’ cell ther­a­py tech

While Flag­ship Pi­o­neer­ing was un­wrap­ping a huge $120 mil­lion round for Ru­bius this morn­ing, the busy ven­ture group al­so launched a biotech on a mis­sion to cre­ate a new type of en­cap­su­lat­ed cell ther­a­py.

Turn­ing to two sci­en­tif­ic founders — MIT’s Daniel An­der­son and the pro­lif­ic Robert Langer — the dis­cov­ery group at Flag­ship has been work­ing on per­me­able bio­ma­te­ri­als that are de­signed to im­plant cells in tis­sue to de­liv­er pro­teins in a sus­tained fash­ion, with­out trig­ger­ing fi­bro­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.